This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk07: Good day, and thank you for standing by. Welcome to the Akibia Therapeutics third quarter 2023 financial results conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that session, you will need to press star 1 1 on your phone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded, and I would now like to hand the conference over to your speaker today, Ms. Mercedes Carrasco. Please go ahead.
spk03: Thank you. Thank you, and welcome to Akebia's third quarter 2023 financial results and business updates conference call. Please note that a press release was issued earlier today, Wednesday, November 8th, detailing our third quarter financial results. and that release is available on the Investors section of our website. For your convenience, a replay of today's call will also be available on our website after we conclude. Joining me for today's call, we have John Butler, Chief Executive Officer, and Ellen Snow, Chief Financial Officer. I'd like to remind everyone that this call includes forward-looking statements. Each forward-looking statement on this call is subject to risks and uncertainties that could cause actual results to differ materially from those described in these statements. Additional information describing these risks is included in the financial results press release that we issued on November 8th, as well as in the risk factors and management discussion and analysis section of our most recent annual and quarterly reports filed with the SEC. The forward-looking statements on this call speak only as of the original date of this call and except as required by law, we do not undertake any obligation to update or revise any of these statements. With that, I'd like to introduce our CEO, John Butler. John?
spk02: Thanks, Mercedes. For those who've been following our story over the past couple of years and have witnessed all of our team's efforts, you know it gives me great pleasure to talk to you about Akibia's future today with an extremely important and hard-fought catalyst in our sights. As we've reported, The FDA set a user fee goal date, or PDUFA date, of March 27, 2024, for Vatadustat, our oral HIF-PH inhibitor to treat anemia due to chronic kidney disease, or CKD, in patients on dialysis. That's less than five months away. Our team has been working diligently towards U.S. approval for Vatadustat. We completed a formal dispute process and engaged with the FDA during an end-of-dispute Type A meeting. We then resubmitted to our NDA for Vatadustat in September. Our resubmission included post-marketing safety data from tens of thousands of patients in Japan where Vatadustat is approved and has been on the market for more than three years. Based on the new data in the resubmission, the FDA assigned a six-month review cycle in line with our prior expectations. Today, they are actively engaged in the review. I just returned from the American Society of Nephrology Kidney Week last week. I was excited to see how much innovation is happening for patients with kidney disease, including multiple products introduced since the meeting last year. I had the pleasure of having many conversations with key medical experts, and I can say unequivocally that these physicians are very excited about the role that Adustat and HIFS can play in the treatment of patients with CKD. they were very happy to share thoughts on where the greatest patient need exists, as well as areas for future research. For our part, we're confident in our path forward and continue to believe in the benefit Vatadustat can deliver to patients. If approved, we're eager to bring Vatadustat to market in the U.S. as an alternative oral treatment to deliver on our commitment to patients, our partners, and the broader kidney community. Before I speak to the potential commercial opportunity for Vatadustat in the US, I want to again applaud our regulatory team for their productive interactions with the FDA over the past year and timely completion of the resubmission. I also want to thank our partner Mitsubishi Tanabe Pharma Corporation, or MTPC, who markets Vatadustat in Japan and was instrumental in collecting the safety data included in the resubmission as part of their typical post-marketing vigilance in Japan. Now, with the regulatory resubmission in our rear view mirror, we're now shifting our focus to the Vatadustat launch phase that we expect next year if Vatadustat's approved. In the international markets, Vatadustat's approved in 36 countries. Since our last call, Vatadustat's been approved in Australia and Taiwan. Work is underway by our partner, Bidisi, to bring Vafseo Vatadustat to market in Europe in 2024. which would generate future royalties and potential milestones for Akibia. That said, a US launch of Atadusat would represent our most significant commercial opportunity. With approval, we have the potential to target an approximately $1 billion market, based on estimates that approximately 88% of the nearly 550,000 patients on dialysis would be treated with an erythropoiesis stimulating agent, or ESA, for anemia. These are the injectables that are the standard of care. It's important to highlight that we are already well prepared for a potential launch and have identified important tailwinds we believe will contribute to our success. First, we have our commercial product supply ready to go, awaiting final label post-potential approval. Second, we also have an experienced commercial sales organization actively calling on dialysis centers. We believe there's approximately a 96% overlap between Arixia prescribers and potential Vatadustat prescribers. Importantly, we'll also benefit from our partnership with CSLV4, which enables potential access to 60% of the treatment centers through its collaboration with Fresenius Medical Care and other small and medium-sized providers. While we do expect to invest appropriately in the Vatadustat launch to reflect the significant opportunity, based on our initial preparedness from 2022 and our existing infrastructure, we expect that investment in 2024 to be incremental compared to our current OPEX. Now, it's critical to also understand the unique payment landscape in dialysis. Medications used to treat most dialysis patients in the U.S. are reimbursed as part of a bundle payment made to providers. Included in the bundle payment are funds for an ESA treatment used to manage anemia. To promote innovative drug use for patients in that prospective payment system, CMS implemented a transitional add-on payment adjustment, or TDAPA. For two years post-TDAPA designation, the TDAPA payment would cover the cost of Vatadustat if a physician prescribed their product. Their overall bundle payment does not change. Now, while we continue to work on post-TDAPA payment policy, it's important to recognize that today almost 90% of dialysis patients are treated for anemia, and there are significant dollars in the current bundle payment for the treatment of anemia. We expect to have Vatadustat commercially available quickly following potential approval, but expect minimal initial revenue to be generated in those first months. After the six-month TdapA application process, anticipated to be complete by October of 24, we anticipate the product would be reimbursed and widely available and accessible to patients. As I mentioned earlier, we will have a strong tailwind from our CSLv4 relationship. which will provide a key view of potential access to up to 60% of the dialysis market through CSLV4's collaboration with Fresenius Kidney Care and several small to mid-sized providers with whom they contract. A key bill will receive two-thirds of the profit associated with Vatadustat sales in those centers, net of certain pre-specified costs, and V4 will keep one-third of the profits. Akiva will retain 100% of the economics in markets not covered by our contract, predominantly any sales to DaVita. Now we're also fortunate to be supported through this launch by the robust cash flows from Arixia. Today we reported Arixia net product revenue of $40.1 million in the third quarter. We've guided to $170 to $175 million net product revenue for the year, and I expect we'll come in around $170 million. We expect Rixia revenue to grow in 2024 as we exit unfavorable payer contracts, incrementally expand our commercial and medical footprint, and gain broader access to providers from their interest in learning about Vatadustat if it's approved. Lastly, we were able to delay the cash payments associated with our Pharmacon debt service until October of 2024. which provides us with additional flexibility to invest in the launch of Adadustat as well as other growth opportunities for the company. And to provide more information on our revenue and other financials, I'd now like to turn the call over to Ellen Snow, our Chief Financial Officer. Ellen?
spk01: Good morning, everyone. Our priority continues to be focused on strengthening our balance sheet as we enter a potential launch year. March this quarter by a favorable loan amendment, which strengthened our cash position for 2024. The Pharmacon loan amendment extends the maturity date of our loan to March of 2025 from November 2024 and defers Akebia's quarterly principal payments until October 31, 2024, at which time the company will begin making monthly principal payments through the date of maturity. The favorable modification to payment terms enables us to strategically invest in the VAT adduce debt launch activities, while also continuing to maximize ORIXIA revenue for the remainder of the year and into 2024. Our cash and cash equivalents and restricted cash as of September 30, 2023, totaled $48.2 million, which with cash from operations, we expect to fund planned operations for at least the next 12 months. Contributing to our cash position, total revenues were $42 million for the third quarter of 2023. Net product revenues from sale of Abrixia were $40.1 million for the third quarter of 2023 compared to $42 million for the third quarter of 2022. The decrease is primarily due to a reduction in volume and the impact of shifting payer mix, partially caused by contracting dynamics and a decline in the phosphate binder market. The decline was partially offset by price increases in January of 2023 and July of 2023. While our quarterly revenue was down from last quarter and compared to the third quarter of 2022, this is a similar trend to what we saw last year and we'll still expect strong fourth quarter. And thus, as John mentioned, we believe ArixiaNet product revenue will be around $170 million for the full 2023. We are committed to both maximizing our current business opportunities and pursuing growth initiatives to create value for our shareholders. While Arixie is now a mature brand nearing loss of exclusivity in March of 2025, we expect relatively stable volume next year while benefiting from higher pricing due to exiting certain payer contracts over the next year. In addition, we continue to work to understand the potential impact and opportunity we could realize when phosphate binder binders enter the bundle in 2025. As we look to our cost structure, we continue to focus on cost containment. Cost of goods sold or COGS was $18 million for the third quarter of 2023, compared to $38.3 million for the third quarter of 22. COGS reflects the cost of Arixia, including non-cash and tangible amortization charge of $9 million per quarter through the fourth quarter of 2024. and third-party royalties. The decrease was primarily due to a non-cast charge related to the excess purchase commitments recorded in 2022 and a reduction in inventory write downs and lower volume of sales resulting in reduced product costs for 2023. R&D expenses were $13.3 million for the third quarter of 2023 compared to $28 million for the third quarter of 2022. The decrease was primarily due to a reduction in spending on VAT-adduced debt development, including clinical trial costs and curtailment of outsourced contract services. SG&A expenses were $22.7 million for the third quarter of 2023, compared to $31.9 million for the third quarter of 2022. Primarily as a result of the reduction in headcount-related costs, the benefits realized from the assignment of the Boston lease in May of 2023 and a targeted cutback in Arixia marketing and promotional expenses that were offset by some one-time non-recurring expenses. Net loss was $14.5 million for the third quarter of 2023, compared to a net loss of $54.1 million for the third quarter of 2022. We continue to find ways of operating more efficiently, placing an increased scrutiny on all areas of operating expenses. We are deliberate about managing expenses in our efforts to further extend our cash one way, until the potential launch of that is used out here in the U.S. Revenue from Arixia continues to provide cash for operations, and we are excited that we have a PDUFA date of March 27, 2024. The entire leadership team remains energized and focused on delivering an alternative oral treatment to patients if approved by the FDA. With that, we will now open the call for questions. Operator?
spk07: Thank you. As a reminder, to ask a question, please press star 1-1 on your phone and wait for your name to be announced. To withdraw your question, please press star 1-1 again. Stand by as we compile the Q&A roster.
spk06: One moment for our first question. Our first question will come from Allison Bratzel of Piper Sandler. Your line is open. Pardon me, Alison Brackel, your line is open. You may ask your question.
spk07: If your phone is on mute, please unmute your line.
spk06: If you're using a headset, please put on your headphones. Chris, why don't we move to the next question? We'll come back to Ali. Okay. Thank you. One moment, please. One moment, please, for our next question.
spk07: The next question will come from Julian Harrison of BTIG. Your line is open.
spk05: Hi, congrats on the recent progress, and thank you for taking my question. First, both Vatadustat and Daprodustat have been on the market in Japan for several years now, so I guess I'm curious if there's anything from the experience there that informs you about how the two drugs should coexist in the U.S. going forward. And then it sounds like the cross-selling opportunity between Arixia and potential Vataducet prescribers is likely significant. So I was just wondering if you could talk more about how you plan to leverage that.
spk02: Julian, thanks for your question. So, you know, we often get asked about the experience in Japan and what there is to learn. And it's It's tough to really point to much because it's such a different market. For one thing, of course, the product is available for dialysis patients and non-dialysis patients. For another, there are, I think it's five HIF-PHIs that are available on the market in Japan. So you have a very different kind of commercial dynamic there as well. But what we have seen is kind of steady adoption of the HIF PHIs into the market. So, you know, as we would expect to see with a new class, you know, it's taken some time for, you know, for it to kind of move into normal use. But, you know, I think we're seeing that become more and more common now across Japan. Of course, when there's five companies promoting the product, you do have, you know, a lot more kind of share of voice across that class. But it's just, you know, again, you know, as we said, we've always wanted the non-dialysis market opportunity as well, right? And that is where you're seeing more of the use and more of the focus from all of the companies, but you're seeing dialysis adoption as well. And then your second question was about, you know, the overlap. And I mean, this is, you know, you can go back to 2018 when we closed the transaction, you know, with Carex and created a commercial company in Akebia. It was with the expressed desire to pick up that leverage, right? The idea that we have this commercial organization in place that's already calling on nephrologists in dialysis centers has deep relationships with them. Of course, we didn't hope for this two-year delay on when we'd be able to take advantage of that leverage, but we think that's extraordinarily important. We have a very experienced sales organization. As I said, I think we'll need to incrementally increase that group. But, you know, we'll do that quickly and Arixio will benefit from that as much as Vatadustat will. But, you know, when you look at any of your, you know, your presence at ASN or any other, you know, kind of marketing opportunity, you basically get the leverage of having two products in the market. And I think it's important also, and I kind of referenced this in my prepared remarks, that when Vataduce that's approved, assuming Vataduce that's approved, physicians will be very interested in talking to reps about that new product. You remember, Orixia is an eight or nine-year-old product. It's not quite as easy to get access to physicians. With that access, they obviously have the opportunity to talk about Orixia as well. In my past, I've seen significant organic growth from the more mature product when you have the opportunity to improve your access to the people who write the prescriptions. And I think that will be an important point of leverage. Excellent.
spk05: Thanks very much.
spk02: Thank you, Julian.
spk07: Thank you. Again, to ask a question, please press star 11 on your phone and wait for your name to be announced. To withdraw your question, please press star 11 again.
spk06: One moment, please, for our next question.
spk07: Our next question will come from Ed Arcee of HC Wainwright and Company. Your line is open.
spk04: Hi, John and Ellen. Thanks for taking my questions. And sorry I missed you this past weekend in Philadelphia. Three questions from me. Firstly, on the launch, just wanted to ask, prior to the Tdapa, which you expect in October of next year, What kind of activities will you be focused on those first six months as you prepare for meaningful sales ramp? And then once you do get to Tdapa, could you just review again the sort of perspective from the dialysis centers on the financial incentives that would be in place once Tdapa is designated. Secondly, I wanted to ask about pricing, especially relative to GSK, and what your thoughts there, if you can share anything. And then lastly, just wanted to ask again about the addressable market. I think you said in your prepared remarks it was 550 or 575, and there's a small percentage that do not take any medications So I just wanted to tie that down a little better. Thanks again.
spk02: Sure, Ed. Thank you for the question. Sorry I missed you last weekend. I hope you enjoyed the meeting as much as I did. So just the last one first. So there's about 550,000 dialysis patients, and about 90%, 88% are on an ESA. today. So, you know, there's always that small percentage of patients who, you know, aren't, don't need to be treated very late stage or, you know, or early and their hemoglobins are still, you know, some start dialysis with a little bit of residual kidney function, so they don't necessarily need to start an ESA right away. So, but that's still, you know, about a half a million patients that are eligible. You know, you used to be able to say that, The market was growing by two to 5% a year religiously for the last 30 years that I've been in it. But of course, COVID has changed that, really thrown on its head. We've even seen that with the phosphate binder market, that it hasn't quite started to recover. It's starting to, but not quite there. So your questions about launch. So prior to Tdapha, It's actually, I mean, it's frustrating, obviously, to have to wait six months for CMS to provide that Tdapid designation. And you'll see that come in, I think it's around July, if everything goes on the timeline, we would get the HCPCS code. And so, you know, you'd be marching down that. But the dialysis providers really need that time also to prepare for introducing a new product into their protocols, et cetera. You know, there's, there'll be things going on a number of, in a number of different ways. Um, you know, obviously there'll be contracting, uh, that's happening with the dialysis providers. Um, they'll be, you know, our commercial organization will be able to talk about the product. It will be an approved product with an approved label. Uh, physicians will want to learn about the product. So, you know, having those conversations before it's available and explaining to them, the timing, uh, will be critical as well. And maybe the most important work will be done by our medical organization and before CSL's medical organization, where you'll be working with the dialysis providers on those protocols for how the product will be used in the dialysis center. So we won't see, and again, some dialysis providers may, choose to do small experience trials to to develop those protocols. And so you may see some revenue. But I really want to, you know, kind of minimize the idea that that there'll be significant revenue. This is it's, it's really an important six months to be ready to hit the ground and take advantage of that of that two year T DAPA period. And that's, you know, that'll be So that will be critical. We're looking forward to that. And then on the dialysis center side, again, you know, for the patients who are PPS patients, you know, which are, see, 90% of patients on dialysis are Medicare patients. Those used to be almost all prospective payment system or PPS payments patients. When Medicare Advantage was introduced into dialysis, that has moved quickly and it's close to 40 to 50% of dialysis patients now. So the MA area is a little more challenging since they're individual contracts. Each provider has a different contract and they're a little hit and miss and we're still trying to understand and help ensure that there's this separate payment available for those MA patients. So that's more work we'll be doing even, you know, from today. But on those 50% of patients who are PPS patients, it's very clear that this TdapA designation pays for Vatadustat on an ASP basis. So whenever the product is used, the dialysis center will bill for the cost of Vatadustat and CMS will determine ASP and reimburse at that rate. You know, basically what that means is, you know, they have a fixed payment. I believe the bundled payment is $280 of dialysis sessions, something like that, for next year and the final rule. And that includes the dollars that they would spend on an ESA. So, you know, dialysis providers, they have the confidence that they're going to get paid for Vatadustat on a cost basis. And they don't have to purchase the ESA You know, they look at that as an opportunity to use an innovative product and, you know, potentially a cost saving for them as well. And, you know, that's something that, you know, obviously is important as dialysis providers. Medicare patients are not where dialysis providers make their money. So any opportunity they can have to squeeze those costs down, they look for that opportunity. And I think your last question was on pricing. And of course, we're not prepared to talk about pricing for Vatadustat yet. You know, we've always talked about kind of understanding the market and the market, the price in the market for ESAs has gone down pretty substantively over the last few years. Interestingly, if you look at the wholesale cost pricing of Dsduvrok or Vatadustat from GSK, if you look at the average dose from their phase three study that would indicate about an eight thousand dollar a year pricing um now you know we've indicated that the opportunity for premium pricing exists and i think that they've seen uh that as well certainly during the tdapa period so um you know we don't know what their contract pricing is and you know we don't have any indication that it's going to be significantly lower than that uh than that number so you know that certainly helps inform us as we think about our pricing for the Vatadustat launch. Great. Thanks, John. That's very helpful. Thank you, Ed. Thank you. Were we able to get Allie back, Chris?
spk07: Yes. One moment, please. And again, to ask a question, please press star 1-1 on your phone. One moment, please, for our next question.
spk06: And again, we have Allison Bratzel of Piper Sandler. Your line is open. Again, Ms. Bratto. One moment. Ms. Bratto, if you're online.
spk02: It looks like we have, luckily, multiple ways of communicating these days. So Allie emailed Mercedes her questions. Mercedes will play Allie today.
spk03: I'll jump in. Thank you very much, Chris. All right, let's start with current cash burn and runway guidance. Ellen, can you talk through the runway, the cash runway guidance, especially with the loan agreement and how that might change things?
spk01: Yes, thank you. We don't provide OpEx guidance, but that said, Averxia continues to contribute meaningful cash to fund operations, and we have a disciplined approach to spending and continue to streamline and become more efficient in our operations. We're extremely happy with where we landed on our Pharmacon amendment and giving us the opportunity to invest incrementally costs to support the Vatadustat launch. And we believe we have sufficient cash to fund operations well through 2024. Great. Great.
spk03: Thank you, Ellen. And then just to build on the question on potential pricing for Vatadustat, how might you be thinking about pricing once the Tdapa period ends?
spk02: That's an important question. So, you know, as we talked about, you know, Tdapa, you've got, you know, kind of that two-year window where you're outside of the dialysis bundle. When Tdapa ends, in the final rule that came out just a couple of weeks ago, basically the way CMS has looked at it is they look at the overall utilization of a product that was part of Tdapa, And then they basically take those dollars and spread it over all of the dialysis sessions that are provided. So for a product that has very limited use in a very small number of patients, that's really challenging. It doesn't really provide the dialysis providers the cash if they have one or two patients that are getting a drug. great thing for Vatadustad is, you know, as we talked about, dialysis, anemia is treated in 90% of dialysis patients, and there are significant dollars already in the bundle. So, you know, thinking about that pricing and that post-TDAPA policy is a little bit more straightforward. Now, you know, I don't think that that that post-TDAPA policy really encourages innovation long-term. And, you know, one of the things being part of the Kidney Care Partners, the lobbying coalition, this is a key area of focus for us and, you know, kind of creating a better way to incorporate innovation into treatment of these patients. So we're going to continue to lobby on the Hill and with CMS to have those dollars follow the patient. And that's a real opportunity for us. So if we think about the environment today though, whatever pricing you have during your Tdapa period, you are going to have to adapt that pricing to kind of what's in the bundle, you know, moving forward. So, you know, there will be, and we'll kind of see where our pricing strategy lands, but I do expect that, you know, the contracting price will have to become more aggressive post-TDAPA without a change in that post-TDAPA policy. So, you know, stay tuned as, you know, as that progresses, but that's the way we're thinking about that.
spk03: Great. And on Vatadustat, can you help us frame the base case expectation on the label, particularly any differences compared to DAP or Dustat, and whether that will matter for uptake?
spk02: So, obviously, we haven't started labeling discussions with FDA yet. I mean, they're early in their review. But we do think that there are significant differences between the compounds. We know that FDA does frequently have a desire to have class labeling, but there are certain areas that we really believe that the data doesn't support that. You know, we've really tried to address that, you know, those particular areas, you know, as aggressively as we can or as clearly as we can, maybe it's a better word, in our draft labeling to the FDA. But, of course, we will obviously work with the agency to have the product approved and, you know, there's a point where, you know, negotiation ends and you take what you get. you know, from a compound perspective, we really do think that these are very different products. And, you know, some of the areas, you know, like the four months not using the product until patients have been on for four months. If you look at the MACE data from Innovate from incident patients and from the thousand patients who became dialysis patients during treatment, there's no increase in MACE risk seen in that data. So, you know, we've incorporated that into our resubmission feel very strongly about that, and that's the kind of conversation we're looking forward to having with the agency.
spk03: Great. Thanks. And then finally, just on the orexia side once more, Ellen had provided good commentary on volume expectations for next year. Just curious if that factors in any impact from the availability of canapinor, or more broadly, how should we be thinking about the competitive set for orexia moving forward?
spk02: Yeah, so the way we think about Tenapenor, honestly, as a person who's worked in the space for 30 years as a patient advocate, it's exciting to see a product, you know, a new technology come in. What we know, you know, Rixie is a great product. Sevellumar is a great product. You know, they don't manage patients' phosphorus levels to normal. And, you know, we know there's a direct relationship between phosphorus and mortality in dialysis patients. And so managing patients more aggressively, if you will, to a lower phosphorus level is a benefit to patients. And with canapinor, I think they can do that. And that's clearly where the label is written. It is an add-on therapy. So, you know, I didn't mention that as one of the things that can help drive Eryxia sales. There will be more interest in phosphorus management with physicians because they have, and the Ardelix folks will be out there talking about tenapenor as well. And, you know, the idea that patients who have an average phosphorus of six can get to five or four and a half would be a fantastic thing for patient outcomes. And at the end of the day, more focus on phosphate binders or phosphate control only helps eryxia.
spk07: Great. Thank you. I'm seeing no further questions in the queue. I would now like to turn the conference back to John Butler for closing remarks.
spk02: Thanks, Chris. And thanks everyone for your questions. We're now nearly through 2023. I just want to reiterate how well positioned we believe Akibi is to close the year. Our team is committed to our strategic objectives. We're eager to bring Vataducet to patients in the US if approved, and we'll work to ensure Vataducet is available globally through our commercial partnerships. will advance our pipeline and grow our revenue in the years ahead. We believe our efforts will help create sustained value for our shareholders while continue towards our purpose to better the lives of people impacted by kidney disease. Thanks, everyone, for joining us today. I look forward to updating you in the future.
spk07: This concludes today's conference call. Thank you all for participating. You may now disconnect and have a pleasant day.
Disclaimer